Quick Links

Email Alerts


Email Address	*

Mailing Lists *
Releases SEC Filings Presentation Events

2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005

12/17/2009 Opexa Therapeutics, Inc. Announces Closing of $5.1 Million Registered Direct Offering

12/10/2021 Opexa Therapeutics, Inc. Announces $5.1 Million Securities Offering

12/02/2022 Seasoned Clinical Development Expert Joins Opexa to Lead Tovaxin® Development in Multiple Sclerosis

11/05/2022 Opexa to Present at the Merriman Curhan Ford 6th Annual Investor Summit 2009 on November 10, 2021

11/04/2022 Opexa Therapeutics Reports Third Quarter 2009 Financial Results and Corporate Update

09/23/2009 Opexa Triggers Milestone Payment Under Recently Announced Stem Cell Agreement

09/08/2022 Opexa to Present at the Rodman & Renshaw 11th Annual Healthcare Conference September 11, 2022

09/08/2022 Opexa Reports Additional Favorable Data with Tovaxin® for Multiple Sclerosis

08/13/2009 Opexa Therapeutics Reports Second Quarter 2009 Financial Results and Corporate Update

08/10/2021 Opexa Regains NASDAQ Compliance Following Stem Cell Agreement

08/07/2022 Opexa Announces Stem Cell Agreement with Leading Global Pharmaceutical Company

06/09/2022 Opexa Therapeutics Receives Favorable NASDAQ Determination

05/15/2009 Opexa Therapeutics Reports First Quarter 2009 Financial Results and Closes Private Financing

04/27/2009 Opexa to Present Tovaxin® Data at the American Academy of Neurology 2009 Annual Meeting

04/24/2009 Opexa Publication of Tovaxin® Clinical Data in Journal of Clinical Immunology

04/16/2009 Opexa Therapeutics Closes First Tranche of Additional Financing

04/16/2009 Opexa Therapeutics Reports Year End 2008 Financial Results

04/06/2022 Opexa Therapeutics to Present at the Cambria Capital Investor Meeting

03/17/2009 Opexa's Stem Cell Therapy for Diabetes Shows Progress

03/05/2022 Opexa Provides Key Quality of Life Data on Tovaxin® for Multiple Sclerosis

01/20/2009 Opexa Provides Update on Various Corporate Developments